Nothing Special   »   [go: up one dir, main page]

MX2007011079A - Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1). - Google Patents

Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1).

Info

Publication number
MX2007011079A
MX2007011079A MX2007011079A MX2007011079A MX2007011079A MX 2007011079 A MX2007011079 A MX 2007011079A MX 2007011079 A MX2007011079 A MX 2007011079A MX 2007011079 A MX2007011079 A MX 2007011079A MX 2007011079 A MX2007011079 A MX 2007011079A
Authority
MX
Mexico
Prior art keywords
spiro
neurokinin
diaza
nonane derivatives
activity
Prior art date
Application number
MX2007011079A
Other languages
English (en)
Inventor
Sophie Coupa
Frans Eduard Janssens
Bruno Schoentjes
Alain Philippe Poncelet
Yvan Rene Ferdinand Simonnet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of MX2007011079A publication Critical patent/MX2007011079A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Esta invencion se relaciona con derivados sustituidos de diaza-espiro-[4.4]-nonano que tienen actividad antagonista de la neurocinina, en particular una actividad antagonista de NK1, su preparacion, composiciones que los comprenden y su uso como una medicina, en particular para el tratamiento y/o profilaxis de la esquizofrenia, emesis, ansiedad y depresion, sindrome del intestino irritable (IBS), perturbaciones del ritmo circadiano, preeclampsia, nocicepcion, dolor, en particular dolor visceral y neuropatico, pancreatitis, inflamacion neurogenica, asma, enfermedad pulmonar obstructiva cronica (COPD) y trastornos de la miccion, tales como incontinencia urinaria; los compuestos de acuerdo con la invencion pueden representarse por la Formula (I) general y comprenden tambien las sales de adicion de acido o base farmaceuticamente aceptables de los mismos, las formas estereoquimicamente isomericas de los mismos, la forma de N oxido de los mismos y profarmacos de los mismos, en donde todos los sustituyentes se definen como en la Reivindicacion 1. (ver formula (I)).
MX2007011079A 2005-03-08 2006-03-03 Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1). MX2007011079A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05101786 2005-03-08
PCT/EP2006/060458 WO2006094948A1 (en) 2005-03-08 2006-03-03 Diaza-spiro-[4.4]-nonane derivatives as neurokinin (nk1) antagonists

Publications (1)

Publication Number Publication Date
MX2007011079A true MX2007011079A (es) 2007-10-08

Family

ID=34938928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007011079A MX2007011079A (es) 2005-03-08 2006-03-03 Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1).

Country Status (15)

Country Link
US (1) US8604200B2 (es)
EP (1) EP1858896B1 (es)
JP (1) JP5078869B2 (es)
KR (1) KR101388453B1 (es)
CN (1) CN101137657B (es)
AT (1) ATE478075T1 (es)
AU (1) AU2006221984C1 (es)
BR (1) BRPI0608847A2 (es)
CA (1) CA2599186C (es)
DE (1) DE602006016244D1 (es)
EA (1) EA014239B1 (es)
ES (1) ES2350647T3 (es)
MX (1) MX2007011079A (es)
NZ (1) NZ556628A (es)
WO (1) WO2006094948A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102070640A (zh) * 2009-11-24 2011-05-25 上海药明康德新药开发有限公司 一种1,7-二氮杂螺[4,5]壬烷及其衍生物的合成方法
US9446029B2 (en) * 2010-07-27 2016-09-20 Colorado State University Research Foundation Use of NK-1 receptor antagonists in management of visceral pain
EP2484674A1 (en) 2011-02-02 2012-08-08 Rottapharm S.P.A. Spiro aminic compounds with NK1 antagonist activity
CN110730662A (zh) * 2017-04-10 2020-01-24 才思治疗公司 用于治疗共核蛋白病的nk1-拮抗剂组合和方法

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4329353A (en) 1980-10-22 1982-05-11 Janssen Pharmaceutica, N.V. 1-(4-Aryl-cyclohexyl)piperidine derivatives, method of use thereof and pharmaceutical compositions thereof
NL8401907A (nl) 1983-06-27 1985-01-16 Sandoz Ag Spirosuccinimiden en werkwijzen voor het bereiden en toepassen van deze spirosuccinimiden.
PH23995A (en) 1984-01-09 1990-02-09 Janssen Pharmaceutica Nv 4((bicycle heterocyclyl)-methyl and hetero)piperidines
US4588722A (en) 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
ES2052544T3 (es) 1986-02-03 1994-07-16 Janssen Pharmaceutica Nv Composiciones anti-histaminicas que contienen n-heterociclil-4-piperidinaminas.
NZ223654A (en) 1987-03-09 1990-03-27 Janssen Pharmaceutica Nv 1-alkyl-substituted-benzimidazole-4-piperidinamines and pharmaceutical compositions
US5403593A (en) 1991-03-04 1995-04-04 Sandoz Ltd. Melt granulated compositions for preparing sustained release dosage forms
FR2676055B1 (fr) 1991-05-03 1993-09-03 Sanofi Elf Composes polycycliques amines et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
IL101850A (en) 1991-06-13 1996-01-31 Janssen Pharmaceutica Nv History 11-) 4-Pipridinyl (-Imidazo] B-1, 2 [] 3 [Benzazepine, their preparation and pharmaceutical preparations containing them
IL101851A (en) 1991-06-13 1996-05-14 Janssen Pharmaceutica Nv History 01 -) 4 - Pipridinyl - and Pipridinylidene (- Imidazo] A-1,2 [Pirolo, Thiano or Purano (] 3,2 [Azpin, their preparation and pharmaceutical preparations containing them and composition
MY110227A (en) 1991-08-12 1998-03-31 Ciba Geigy Ag 1-acylpiperindine compounds.
KR960011370B1 (ko) 1991-12-31 1996-08-22 재단법인 한국화학연구소 스피로알킬아민 유도체와 그의 제조방법
WO1993014083A1 (en) 1992-01-09 1993-07-22 Janssen Pharmaceutica N.V. Pharmaceutically active substituted benzimidazole derivatives
DE69412067T2 (de) 1993-01-28 1999-03-25 Merck & Co., Inc., Rahway, N.J. Substituierte spiro-azaringen als tachykinine rezeptor antagonisten
US5635510A (en) 1993-05-06 1997-06-03 Merrell Pharmaceuticals Inc. Substituted pyrrolidin-3-yl-alkyl-piperidines
GB9310066D0 (en) 1993-05-17 1993-06-30 Zeneca Ltd Alkyl substituted heterocycles
CA2163995A1 (en) * 1993-06-07 1994-12-22 Malcolm Maccoss Spiro-substituted azacycles as neurokinin antagonists
JP3681388B2 (ja) 1993-07-13 2005-08-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗アレルギー性イミダゾアゼピン
AU7856194A (en) 1993-10-26 1995-05-22 Ciba-Geigy Ag N-benzoyl-4-oxy/thio-2-substituted piperidines as substance-p receptor antagonists
IL111730A (en) 1993-11-29 1998-12-06 Fujisawa Pharmaceutical Co Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them
GB2287404A (en) 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
JPH10502640A (ja) 1994-07-12 1998-03-10 イーライ・リリー・アンド・カンパニー 異項環タキキニン受容体拮抗物質
RU2156763C2 (ru) 1994-07-15 2000-09-27 Мейдзи Сейка Кабусики Кайся Азотсодержащие гетероциклические производные, фармацевтическая композиция на их основе и способ лечения или профилактики тромботических заболеваний
GB9415996D0 (en) * 1994-08-08 1994-09-28 Merck Sharp & Dohme Therapeutic agents
ATE212981T1 (de) 1994-09-30 2002-02-15 Novartis Erfind Verwalt Gmbh 1-acyl-4-aliphatische aminopiperidin verbindungen
GB9426102D0 (en) 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
US5654316A (en) 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
NZ321575A (en) 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
TW429256B (en) 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
TW382017B (en) 1995-12-27 2000-02-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(fused imidazole)-piperidine derivatives
TW531537B (en) 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
GB9600235D0 (en) 1996-01-05 1996-03-06 Pfizer Ltd Therapeutic agents
WO1997025988A1 (en) 1996-01-17 1997-07-24 Eli Lilly And Company Methods of treating or preventing pain or nociception
JP3192631B2 (ja) 1997-05-28 2001-07-30 三共株式会社 飽和複素環化合物からなる医薬
GB9714129D0 (en) 1997-07-04 1997-09-10 Pfizer Ltd Azetidines
AU9540898A (en) 1997-08-29 1999-03-22 Dsm N.V. Granules free of excipients
US5997464A (en) 1997-08-29 1999-12-07 Orthosoft, L.L.C. Magnetic coil for pulsed electromagnetic field
GB9723544D0 (en) 1997-11-07 1998-01-07 Merck Sharp & Dohme Therapeutic agents
AU2206699A (en) 1997-12-23 1999-07-12 Alcon Laboratories, Inc. Muscarinic agents and use thereof to treat glaucoma, myopia and various other conditions
CN1165533C (zh) * 1998-01-23 2004-09-08 三共株式会社 螺哌啶衍生物
GB9904786D0 (en) 1999-03-02 1999-04-28 Merck Sharp & Dohme Therapeutic agents
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
US6759520B1 (en) 1999-10-28 2004-07-06 The New England Medical Center Hospitals, Inc. Chimeric analgesic peptides
US6482829B2 (en) 2000-06-08 2002-11-19 Hoffmann-La Roche Inc. Substituted heterocyclic siprodecane compound active as an antagonist of neurokinin 1 receptor
WO2002014271A1 (fr) 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Dérivés de proline et leur utilisation comme médicaments
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
WO2002085355A1 (en) 2001-04-18 2002-10-31 Euro-Celtique, S.A. Spiropyrazole compounds
AU2002342238B2 (en) 2001-05-14 2007-01-25 F. Hoffmann-La Roche Ag 1-oxa-3,9-diaza-spiro'5,5!undecan-2-ones derivatives and its use as antagonist of the neurikinin receptor
DE60236206D1 (de) 2001-12-28 2010-06-10 Acadia Pharm Inc Spiroazacyclische verbindungen als monoaminrezeptormodulatoren
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
WO2004056772A1 (en) 2002-12-23 2004-07-08 Janssen Pharmaceutica N.V. Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists
MY141736A (en) 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists
DE60322110D1 (de) 2002-12-23 2008-08-21 Janssen Pharmaceutica Nv Substituierte 4-(4-piperidin-yl-piperazin-1-yl)-azntagonisten
JO2485B1 (en) 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
JO2696B1 (en) 2002-12-23 2013-03-03 شركة جانسين فارماسوتيكا ان. في Derivatives of 1-piperdine-4-yl-4-biprolidine-3-yl-piperazine substituted and used as quinine antagonists
FR2854158B1 (fr) 2003-04-25 2006-11-17 Sanofi Synthelabo Derives de 2-acylamino-4-phenylethiazole, leur preparation et leur application en therapeutique
WO2004103305A2 (en) 2003-05-16 2004-12-02 Euroceltique S.A. Spiropyrazole compound
EP1635811A2 (en) 2003-06-10 2006-03-22 Janssen Pharmaceutica N.V. Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments
ATE395062T1 (de) 2003-06-10 2008-05-15 Janssen Pharmaceutica Nv Kombination von opioiden und einem piperazin- derivat für die behandlung von schmerzen
CA2579608A1 (en) 2003-09-10 2005-03-17 Virochem Pharma Inc. Spiro compounds and methods for the modulation of chemokine receptor activity
US7300505B2 (en) * 2003-12-12 2007-11-27 Canon Kabushiki Kaisha Ink-jet recording ink, ink cartridge, recording unit, ink-jet recording method, ink-jet recording apparatus, and method for stabilizing ink ejection
JP2007522160A (ja) 2004-02-10 2007-08-09 エフ．ホフマン−ラ　ロシュ　アーゲー ケモカインｃｃｒ５受容体モジュレーター
JO2676B1 (en) * 2004-04-06 2012-06-17 جانسين فارماسوتيكا ان. في Derivatives of second-aza-spiro- (5,4) -dikan and their use as antihistamines
JO2527B1 (en) * 2004-04-06 2010-03-17 شركة جانسين فارماسوتيكا ان. في Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
WO2005104199A1 (ja) 2004-04-23 2005-11-03 Jsr Corporation 半導体ウエハ用研磨パッド及びこれを備える半導体ウエハ用研磨複層体並びに半導体ウエハの研磨方法

Also Published As

Publication number Publication date
EA014239B1 (ru) 2010-10-29
NZ556628A (en) 2009-09-25
WO2006094948A1 (en) 2006-09-14
CA2599186C (en) 2014-12-09
CA2599186A1 (en) 2006-09-14
DE602006016244D1 (de) 2010-09-30
ES2350647T3 (es) 2011-01-25
EA200701898A1 (ru) 2008-06-30
JP5078869B2 (ja) 2012-11-21
CN101137657A (zh) 2008-03-05
KR101388453B1 (ko) 2014-04-23
US8604200B2 (en) 2013-12-10
EP1858896A1 (en) 2007-11-28
AU2006221984A1 (en) 2006-09-14
EP1858896B1 (en) 2010-08-18
AU2006221984C1 (en) 2012-02-09
CN101137657B (zh) 2011-02-02
BRPI0608847A2 (pt) 2010-02-02
KR20070108905A (ko) 2007-11-13
JP2008532976A (ja) 2008-08-21
US20090221641A1 (en) 2009-09-03
ATE478075T1 (de) 2010-09-15
AU2006221984B2 (en) 2011-04-21

Similar Documents

Publication Publication Date Title
WO2006094934A8 (en) Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
TW200604198A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
WO2010018109A3 (en) Substituted aminotetralines
CY1121543T1 (el) Ενωση πυριδυλαμινοοξεικου οξεος
JO2527B1 (en) Derivatives of second-aza-Spiro- (5,5) -andecan and their use as antihistamines
WO2010018113A3 (en) Bi-aryl aminotetralines
NO20065022L (no) Substituerte 4-alkyl- og 4-alkanoyl-piperidinderivater og deres anvendelse som neurokininantagonister
WO2010018112A3 (en) Monoaryl aminotetralines
MY151172A (en) Pyrimidine amide compounds as pgds inhibitors
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
MX350862B (es) Acidos de piperidinil naftilacetico.
ATE538100T1 (de) Aminotetrahydroindazoloessigsäuren
NZ591914A (en) Naphthylacetic acids
WO2004056799A3 (en) Substituted 1-piperidin-4-yl-4-pyrrolidin-3-yl-piperazine derivatives and their use as neurokinin antagonists
MX2009005507A (es) Derivados de espiro-piperidina.
WO2008087654A3 (en) PIPERIDINES AS INHIBITORS OF 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1
MX2007011079A (es) Derivados de diaza-espiro-[4-4]-nonano como antagonistas de la neurocinina (nk1).
DE602007004327D1 (de) Einen azepin-kern enthaltende antagonisten des histaminrezeptors
WO2006011024A3 (en) New tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them
MX2009005504A (es) Derivados de espiro piperidina como antagonistas del receptor via.
MX2009000762A (es) 4-arilalcoximetil-4-fenil piperidinas y su uso como antagonistas del receptor de neuroquinina para el tratamiento de trastornos del sistema nervioso central.
NO20081483L (no) Kombinasjon av forbindelser som kan brukes ved behandling av respiratoriske sykdommer, spesielt kronisk obstruktiv pulmonaer sykdom (COPD) og astma
MY145168A (en) Substituted diaza-spiro-[4.5]-decane derivatives and their use as neurokinin antagonists
MX2011013149A (es) Acido (s)-2-bencil-3-((3r,4r)-4 - (3 - carbamoilfenil) -3,4-dimetilpiperidinil) propanoico y sales delmismo como antagonistas de receptores opioides.
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).

Legal Events

Date Code Title Description
FG Grant or registration